1st Quarter - Report

ARENTFOX SCHIFF LLP for KEMPHARM, INC.

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse deterrent legislation

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
NORMAN FREDERICK LENT —
SONJA NESBIT —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; White House Office

Pharmacy PHA

FDA regulation of opioid abuse deterrent formulations

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
NORMAN FREDERICK LENT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.